Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Ensem Therapeutics
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
UMC Utrecht
AstraZeneca
University of Chicago
University of California, Irvine
Eastern Cooperative Oncology Group
Eli Lilly and Company
ViroMissile, Inc.
Terremoto Biosciences Inc.
University Health Network, Toronto
Jazz Pharmaceuticals
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
University of Colorado, Denver
MacroGenics
Avacta Life Sciences Ltd
Alliance for Clinical Trials in Oncology
SystImmune Inc.
Daiichi Sankyo
University of Nebraska
Oscotec Inc.
Kidney Cancer Research Bureau
Adela, Inc
Sichuan Baili Pharmaceutical Co., Ltd.
The Netherlands Cancer Institute
Var2 Pharmaceuticals
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Tanabe Pharma America, Inc.
MediLink Therapeutics (Suzhou) Co., Ltd.
Rutgers, The State University of New Jersey
LigaChem Biosciences, Inc.
British Columbia Cancer Agency
Washington University School of Medicine
Travera Inc
Jonsson Comprehensive Cancer Center
Centre for Research and Technology Hellas
University of California, Irvine
ModeX Therapeutics, An OPKO Health Company
The Second Affiliated Hospital of Hainan Medical University
Columbia University